Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies
- 31 August 2018
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 58 (7) , 788-794
Abstract
The term “off‐label drug use” involves the prescription of medications for unapproved indications or in unapproved dosage, dosage form, or route of administration. Off‐label medications are common in the management of dermatologic diseases. In the recent years, new indications for botulinum toxin, biologics, spironolactone, topical calcineurin, and topical vitamin D analogues emerged, and these drugs are being used off‐label to treat a variety of conditions. The high cost and long time required for the approval discourage pharmaceutical companies from developing studies and pursuing the approval by regulatory agencies. Patients and physicians may have a different perspective regarding the off‐label use of medications. The ethical discussion is based on the different opinions concerning the need for informed consent by the patient and how this could be applicable in the clinical practice.Keywords
This publication has 32 references indexed in Scilit:
- Prescrição Off-Label no Brasil e nos EUA: aspectos legais e paradoxosCiencia & Saude Coletiva, 2013
- France's New Framework for Regulating Off-Label Drug UseNew England Journal of Medicine, 2012
- Ten Common Questions (and Their Answers) About Off-label Drug UseMayo Clinic Proceedings, 2012
- Informed Consent for Off-Label Use of Prescription MedicationsAMA Journal of Ethics, 2012
- Off-Label Prescribing: A Call for Heightened Professional and Government OversightJournal of Law, Medicine & Ethics, 2009
- Informed Consent and Shared Decision-Making: A Requirement to Disclose to Patients Off-Label PrescriptionsPLOS Medicine, 2008
- Off-Label Promotion, On-Target SalesPLOS Medicine, 2008
- Regulating Off-Label Drug Use — Rethinking the Role of the FDANew England Journal of Medicine, 2008
- ‘Off-label’ drug use: an FDA regulatory term, not a negative implication of its medical useInternational Journal Of Impotence Research, 2007
- The spironolactone renaissanceExpert Opinion on Investigational Drugs, 2001